Retatrutide: What to Expect From Clinical Trials

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly, currently under clinical evaluation with no marketing authorisation in the UK or elsewhere. Understanding what to expect on retatrutide means looking closely at what authorised clinical trials have reported, including the side effects observed, the populations studied, and the regulatory position. This article sets out the available trial evidence, the known safety considerations, and the important distinction between accessing retatrutide through an authorised clinical trial and the serious risks associated with unregulated online sources.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide is an investigational triple receptor agonist (GLP-1, GIP and glucagon) with no MHRA marketing authorisation; it is available only to participants enrolled in authorised clinical trials.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it cannot be prescribed or supplied outside an authorised clinical trial.^[1][2] It is an investigational medicine developed by Eli Lilly that acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[7][8] This triple agonist mechanism is designed to influence appetite regulation, energy expenditure and glucose metabolism through complementary pathways. Because it targets three receptors rather than the one or two targeted by currently licensed medicines, it is sometimes described in research literature as a triple receptor agonist, though no head-to-head trials against licensed treatments have been conducted.

The MHRA has not authorised retatrutide, and no UK launch date can be given. The medicine is currently being evaluated in a Phase 3 clinical programme known as TRIUMPH, which includes multiple trials across different patient populations (registered on ClinicalTrials.gov). A separate Phase 3 programme, TRANSCEND-T2D-1, has reported findings in people with type 2 diabetes.^[5][6] Until the MHRA reviews a completed marketing authorisation application and grants approval, retatrutide remains available only to participants enrolled in authorised clinical trials.

Anyone who believes they may be eligible for a trial can discuss this with their GP, who can advise on whether a referral to a research centre is appropriate. UK patients can also search for authorised trials via the NIHR Be Part of Research portal (bepartofresearch.nihr.ac.uk). Note that enrolment itself is carried out by the research team, not by a GP. Licensed weight-management treatments are available and can also be discussed with a GP.

What did clinical trials actually find about retatrutide?

A Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) reported a mean body weight reduction of approximately 24% at the highest dose over 48 weeks, though these findings cannot predict individual outcomes.

The most widely cited early data on retatrutide come from a Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.), which enrolled adults with obesity or overweight and evaluated several doses over 48 weeks. In that trial, participants receiving the highest dose studied achieved a mean body weight reduction of approximately 24% from baseline. These are trial findings in a specific population under controlled conditions and cannot be taken as a prediction of what any individual would experience.

The Phase 3 TRIUMPH programme includes TRIUMPH-1 through TRIUMPH-4, designed to provide evidence across larger and more diverse populations with longer follow-up and more rigorous safety monitoring. Initial topline results from some TRIUMPH trials have been presented at scientific congresses; full peer-reviewed publications are awaited, and the evidence base continues to develop. The TRANSCEND-T2D-1 Phase 3 trial, published in The Lancet, examined retatrutide in adults with type 2 diabetes and reported reductions in both body weight and HbA1c.^[5][6]

As with all trial data, results reflect outcomes in participants who met specific eligibility criteria. These typically exclude people who are pregnant, breastfeeding or planning pregnancy, among other conditions. Participants in these trials are also required to use effective contraception as specified by each trial protocol; readers interested in the precise requirements for a particular trial should consult the relevant ClinicalTrials.gov record or discuss this with the trial team.

It is important to note that trial populations, standardised conditions and close clinical monitoring mean that results observed in trials may differ from outcomes seen in routine clinical practice. No conclusions about comparative effectiveness against licensed medicines can be drawn from these data, as no direct head-to-head trials have been conducted.

What side effects have been reported in retatrutide trials?

The most commonly reported side effects are gastrointestinal, including nausea, vomiting and diarrhoea; heart rate increases and acute pancreatitis risk are additional safety considerations being monitored in Phase 3 trials.

The side effects reported in retatrutide trials are broadly consistent with those seen with other medicines acting on GLP-1 receptors, though the addition of glucagon receptor agonism introduces some distinct considerations. In the Phase 2 trial, the most commonly reported adverse effects were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation. These effects were generally more frequent at higher doses and tended to occur during dose escalation, often reducing in intensity over time. Injection-site reactions were also reported.

Acute pancreatitis has been reported with GLP-1 receptor agonist class medicines, and this remains a safety consideration for retatrutide.^[13] Trial protocols for this class of medicine have generally excluded participants with a personal or family history of pancreatitis; readers should consult the relevant trial protocol or ClinicalTrials.gov record for the specific criteria applicable to any retatrutide trial. Heart rate increases have also been observed in retatrutide trial data, consistent with the known pharmacological effects of glucagon receptor agonism reported in the Phase 2 trial and being monitored in the ongoing Phase 3 programme.^[14][15]

People with pre-proliferative or proliferative diabetic retinopathy should be aware that this subgroup warrants particular caution with GLP-1-based therapies as a class.^[16][17] Anyone in this category who is considering trial participation should discuss the implications with their ophthalmologist and the trial team before consenting.

Because retatrutide is investigational, its full safety profile has not yet been established. Participants in authorised trials are monitored closely, and any adverse events must be reported to the trial team under the study protocol. Trial participants are advised to carry their study identification card and to inform any emergency or urgent care clinician that they are taking part in a clinical trial; serious symptoms should be reported to the trial team promptly, as per the protocol. Suspected side effects of a medicine being taken outside a clinical trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; participants in a clinical trial should report adverse events through the trial team or sponsor as directed by the study protocol. No safety conclusions applicable to the general population can yet be drawn, and the ongoing TRIUMPH trials are specifically designed to characterise the safety profile more comprehensively across a broader range of participants.

Is it safe to buy retatrutide online?

It is not legal or safe to purchase retatrutide online in the UK; any product sold under this name is unlicensed and may be counterfeit, contaminated or incorrectly dosed.

It is not possible to legally purchase retatrutide online in the UK, and anything sold online under this name is not a licensed product and may be falsified or counterfeit. Because retatrutide has no marketing authorisation anywhere in the world, there is no legitimate commercial supply chain. Any website claiming to sell retatrutide is not operating within the law, and the product being sold cannot be verified for identity, purity, concentration or safety. Counterfeit injectable medicines carry serious risks, including contamination, incorrect dosing and the presence of unknown substances.

The MHRA actively monitors the online sale of unlicensed medicines and has warned consumers about the dangers of purchasing injectable weight-management products from unregulated sources.^[20][3] If you encounter a website offering retatrutide for sale, you should not purchase from it. Suspected illegal online sellers of medicines can be reported to the MHRA directly via the reporting form on the MHRA website (gov.uk/report-problem-medicine-medical-device). Legitimate online pharmacies registered with the General Pharmaceutical Council (GPhC) in Great Britain, or the Pharmaceutical Society of Northern Ireland (PSNI) in Northern Ireland, are listed on their respective registers at pharmacyregulation.org and psni.org.uk. However, even a registered pharmacy cannot legally supply retatrutide, as it is not an authorised medicine.

If you are interested in weight management support, speak with your GP about licensed options that are currently available and appropriate for your circumstances. If you are interested in participating in a clinical trial of retatrutide, your GP can advise on whether a referral to a research centre is suitable, and you can also search for trials via the NIHR Be Part of Research portal. Retatrutide can only be accessed within an authorised clinical trial, and no date for any broader availability can be given.

Frequently Asked Questions